NYSE: AVNSAvanos Medical Inc Stock
$18.71-0.05 (-0.27%)
Updated Apr 24, 2024
AVNS Price
$18.71
Fair Value Price
N/A
Market Cap
$864.46M
52 Week Low
$17.24
52 Week High
$30.28
P/E
-14.17x
P/B
0.7x
P/S
1.55x
PEG
N/A
Dividend Yield
N/A
Revenue
$673.30M
Earnings
-$61.80M
Gross Margin
56.4%
Operating Margin
-6.65%
Profit Margin
-9.2%
Debt to Equity
0.37
Operating Cash Flow
$32M
Beta
1.12
Next Earnings
May 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A
AVNS Overview
Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. Its product portfolio includes digestive health products, including enteral feeding tubes and solutions; respiratory health products, such as closed airway suction systems and oral care kits; and acute pain products comprising surgical pain pumps, and cold and compression therapy systems, as well as interventional pain management solutions that include minimally invasive interventional pain therapies. The company sells its products under the MIC-KEY, CORPAK, NEOMED, BALLARD, MICROCUFF, ENDOCLEAR, ON-Q, AMBIT, GAME READY, and COOLIEF brand names. It markets its products directly to hospitals and other healthcare providers, and through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AVNS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AVNS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AVNS is good value based on its book value relative to its share price (0.7x), compared to the US Medical Devices industry average (3.73x)
P/B vs Industry Valuation
AVNS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AVNS due diligence checks available for Premium users.
Be the first to know about important AVNS news, forecast changes, insider trades & much more!
AVNS News
Valuation
AVNS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-14.17x
Industry
30.46x
Market
41.27x
AVNS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.7x
Industry
3.73x
AVNS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AVNS's financial health
Profit margin
Revenue
$173.3M
Net Income
$10.5M
Profit Margin
6.1%
AVNS's Earnings (EBIT) of -$44.80M... subscribe to Premium to read more.
Interest Coverage Financials
AVNS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.7B
Liabilities
$456.1M
Debt to equity
0.37
AVNS's short-term assets ($487.00M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AVNS's short-term assets ($487.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AVNS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AVNS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$12.7M
Investing
$81.0M
Financing
-$114.7M
AVNS's operating cash flow ($32.40M)... subscribe to Premium to read more.
Debt Coverage Financials
AVNS vs Medical Device Stocks
Avanos Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.